Clinical Research Directory
Browse clinical research sites, groups, and studies.
Analgesic Efficacy of Maxigesic in Breast Cancer Surgery
Sponsor: Yonsei University
Summary
The present study aims to find a perioperative analgesic method that provides sufficient analgesia while reducing immune compromise in cancer surgery. This study is to investigate the analgesic effect and safety of Maxigesic inj. (a combination of acetaminophen 1000 mg and ibuprofen 300 mg), which is added to opioid-based IV-PCA in patients undergoing breast cancer surgery.
Official title: Analgesic Efficacy of Maxigesic Added to Opioid Based-PCA in Patients Undergoing Breast Cancer Surgery
Key Details
Gender
FEMALE
Age Range
20 Years - 70 Years
Study Type
INTERVENTIONAL
Enrollment
84
Start Date
2023-12-28
Completion Date
2025-12-26
Last Updated
2025-07-20
Healthy Volunteers
No
Conditions
Interventions
Maxigesic
For postoperative analgesia, 50 mcg of fentanyl was administered 15 minutes before the end of surgery, and IV-PCA (fentanyl 1.0 mcg/kg, ramosetron 0.3 mg, total 250cc, infusion rate 5cc/h, bolus 0.5 cc, lock-out time 15min) is started. Additionally, in the Maxigesic group, one vial of Maxigesic (acetaminophen 1000mg/ ibuprofen 300mg) is administered 15 minutes before the end of the surgery, and 2 vials of Maxigesic are added to the IV-PCA.
0.9% saline solution
For postoperative analgesia, 50 mcg of fentanyl was administered 15 minutes before the end of surgery, and IV-PCA (fentanyl 1.0 mcg/kg, ramosetron 0.3 mg, total 250cc, infusion rate 5cc/h, bolus 0.5 cc, lock-out time 15min) is started. Additionally, in the control group, the same amount of 0.9% saline solution with Maxigesic is administered.
Locations (1)
Department of Anesthesiology and Pain Medicine, Yonsei University College of Medicine
Seoul, South Korea